Table 2.
Clinicopathologic findings for patients with EGFR-mutant solid “pseudosquamous” adenocarcinomas. Both were initially diagnosed as squamous cell carcinomas.
| Patient # | Age | Gender | Race | Smoking status | Stage‡ | Initial diagnosis (site) | Mutation | Re-review | Lines of therapy | EGFR TKI line | Best response to EGFR TKI | TTP on TKI (months) | OS (months) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 12 (11) | 89 | F | Asian | Never | IV | Squamous (lung) | L858R | Adenocarcinoma | 1 | 1st line | SD | 7.6 | 16.5 |
| 13 (12) | 53 | F | White | Former (31) | IV** | Squamous (lung) | exon 19 del | Adenocarcinoma | 1 | 1st line | PR | 12.4 | 20.6+ |
#
In parentheses are corresponding patient IDs in reference (8)
**
Prior Stage IB s/p adjuvant cis/doce followed by RLL lobectomy